Systemic Absorption of Orally Administered Neomycin in Liver Disease
- 25 February 1960
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 262 (8) , 385-389
- https://doi.org/10.1056/nejm196002252620803
Abstract
NEOMYCIN was introduced by Waksman and Lechevalier1 as an antibiotic active against organisms resistant to streptomycin. It was first given to patients with intractable tuberculosis or urinary infections, but was found to damage readily the kidney, the eighth nerve and possibly the liver.2 3 4 Waisbren and Spink5 gave neomycin parenterally to 63 patients and found evidence of transient renal damage in 24 cases, and 5 patients became deaf. At autopsy in their fatal cases, as in those of others,6 7 8 9 the kidneys showed severe tubular necrosis. Some of these authors also reported permanent perception deafness and occasionally vestibular damage; these sometimes developed . . .Keywords
This publication has 8 references indexed in Scilit:
- NEOMYCIN IN THE TREATMENT OF HEPATIC COMAThe Lancet, 1957
- ELECTROLYTE AND CIRCULATORY CHANGES IN TERMINAL LIVER FAILUREThe Lancet, 1956
- Episodic Stupor Following Portacaval ShuntNew England Journal of Medicine, 1956
- NEOMYCIN NEPHROPATHYJAMA, 1956
- XCVI The Ototoxicity of Dihydrostreptomycin and Neomycin in the CatAnnals of Otology, Rhinology & Laryngology, 1953
- NEOMYCIN THERAPYJAMA, 1951
- A CLINICAL APPRAISAL OF NEOMYCINAnnals of Internal Medicine, 1950
- Neomycin, a New Antibiotic Active against Streptomycin-Resistant Bacteria, including Tuberculosis OrganismsScience, 1949